In addition to examining research trends, hotspots, and boundaries from 2014 to 2023, this study aimed to conduct a bibliometric analysis in the field of immunotherapy for patients with NSCLC carrying KRAS mutations. Here, KRAS is linked to non-small cell lung carcinoma.